Glucógeno sintasa quinasa 3 (GSK3) como diana de fármacos anti-Alzheimer
Loading...
Official URL
Full text at PDC
Publication date
2015
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Abstract
El Alzheimer es una enfermedad neurodegenerativa en la que el tratamiento actual se basa en compuestos que disminuyen los síntomas, mejorando la calidad de vida de los pacientes durante unos años, aunque no tienen acción a largo plazo. La enzima GSK3 se ha visto que interfiere en el desarrollo de la enfermedad, interactuando tanto con las placas seniles como con los ovillos neurofibrilares, por lo que se pensó que podría ser una buena diana terapéutica para evitar el desarrollo y permitir la remisión de la enfermedad. A día de hoy se han desarrollado numerosos compuestos que han mostrado actividad en la inhibición de la enzima. A pesar de ello, muy pocos se han llegado a desarrollar más allá de estudios preclínicos, muchas veces causado por la falta de selectividad o la excesiva inhibición. El tideglusib ha sido el que más lejos ha llegado en los estudios clínicos, aunque estudios recientes han demostrado que no existe una eficacia clínica significativa. Probablemente, en un futuro se empleara una terapia combinada para poder conseguir revertir el desarrollo de la enfermedad.
Alzheimer's disease is a neurodegenerative disease whose current treatment is based on compounds which decrease the symptoms, improving the life’s quality of patients for a few years, but no long-term action. The GSK3 has been shown to interfere with the development of the disease, interacting with both senile plaques and neurofibrillary tangles, so it was thought that could be a good therapeutic target for preventing the development and for allowing remission. Nowadays, a huge amount of compounds have been developed showning activity in inhibiting the enzyme. However, very few compounds have come to develop beyond preclinical studies, often caused by lack of selectivity or excessive inhibition. Tideglusib has been the furthest compound along in clinical trials, although recent studies have shown there is a significant clinical efficacy. Probably in the future, the combination therapy will be employed to achieve reverse the development of the disease.
Alzheimer's disease is a neurodegenerative disease whose current treatment is based on compounds which decrease the symptoms, improving the life’s quality of patients for a few years, but no long-term action. The GSK3 has been shown to interfere with the development of the disease, interacting with both senile plaques and neurofibrillary tangles, so it was thought that could be a good therapeutic target for preventing the development and for allowing remission. Nowadays, a huge amount of compounds have been developed showning activity in inhibiting the enzyme. However, very few compounds have come to develop beyond preclinical studies, often caused by lack of selectivity or excessive inhibition. Tideglusib has been the furthest compound along in clinical trials, although recent studies have shown there is a significant clinical efficacy. Probably in the future, the combination therapy will be employed to achieve reverse the development of the disease.